These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 29704489)

  • 21. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful Prediction of Human Pharmacokinetics After Oral Administration by Optimized Physiologically Based Pharmacokinetics Approach and Permeation Assay Using Human Induced Pluripotent Stem Cell-Derived Intestinal Epithelial Cells.
    Mayumi K; Akazawa T; Kanazu T; Ohnishi S; Hasegawa H
    J Pharm Sci; 2020 Apr; 109(4):1605-1614. PubMed ID: 31884012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute.
    Smits A; De Cock P; Vermeulen A; Allegaert K
    Expert Opin Drug Metab Toxicol; 2019 Jan; 15(1):25-34. PubMed ID: 30554542
    [No Abstract]   [Full Text] [Related]  

  • 25. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
    Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
    Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
    Sadiq MW; Nielsen EI; Khachman D; Conil JM; Georges B; Houin G; Laffont CM; Karlsson MO; Friberg LE
    J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):69-79. PubMed ID: 27578330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.
    Sayama H; Komura H; Kogayu M; Iwaki M
    J Pharm Sci; 2013 Nov; 102(11):4193-204. PubMed ID: 24018828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.
    Dallmann A; Ince I; Solodenko J; Meyer M; Willmann S; Eissing T; Hempel G
    Clin Pharmacokinet; 2017 Dec; 56(12):1525-1541. PubMed ID: 28391404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Generic Methods to Predict Human Pharmacokinetics Using Physiologically Based Pharmacokinetic Model for Early Drug Discovery of Tyrosine Kinase Inhibitors.
    Ren HC; Sai Y; Chen T
    Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):121-132. PubMed ID: 30039459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole-Body Physiologically Based Pharmacokinetic Modeling of Trastuzumab and Prediction of Human Pharmacokinetics.
    Bae DJ; Kim SY; Bae SM; Hwang AK; Pak KC; Yoon S; Lim HS
    J Pharm Sci; 2019 Jun; 108(6):2180-2190. PubMed ID: 30716331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of the Number of Tissue Groups of Kinetically Distinct Transit Time in Whole-Body Physiologically Based Pharmacokinetic (PBPK) Models II: Practical Application of Tissue Lumping Theories for Pharmacokinetics of Various Compounds.
    Jeong YS; Kim MS; Chung SJ
    AAPS J; 2022 Aug; 24(5):91. PubMed ID: 36002779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Machine learning and artificial intelligence in physiologically based pharmacokinetic modeling.
    Chou WC; Lin Z
    Toxicol Sci; 2023 Jan; 191(1):1-14. PubMed ID: 36156156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals.
    Shimizu H; Yoshida K; Nakada T; Kojima K; Ogasawara A; Nakamaru Y; Yamazaki H
    Drug Metab Dispos; 2019 Feb; 47(2):114-123. PubMed ID: 30420404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach.
    Malmborg J; Ploeger BA
    J Pharmacol Toxicol Methods; 2013; 67(3):203-13. PubMed ID: 23280406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vitro-In Vivo Correlation Using In Silico Modeling of Physiological Properties, Metabolites, and Intestinal Metabolism.
    Choi SM; Kang CY; Lee BJ; Park JB
    Curr Drug Metab; 2017; 18(11):973-982. PubMed ID: 29086683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.
    Heikkinen AT; Lignet F; Cutler P; Parrott N
    Proteomics Clin Appl; 2015 Aug; 9(7-8):732-44. PubMed ID: 25676057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data.
    Choi S; Han S; Lee SJ; Lim B; Bae SH; Han S; Yim DS
    Comput Methods Programs Biomed; 2022 Apr; 216():106662. PubMed ID: 35151112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.